Jazz Pharmaceuticals plc (JAZZ)
| Previous Close | 117.28 |
| Open | 117.50 |
| Bid | 117.06 x 200 |
| Ask | 118.03 x 200 |
| Day's Range | 117.30 - 117.81 |
| 52 Week Range | 99.06 - 137.39 |
| Volume | |
| Avg. Volume | 677,545 |
| Market Cap | 7.244B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 19.88 |
| EPS (TTM) | 5.90 |
| Earnings Date | Nov 05, 2024 - Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 178.71 |
TipRanksJazz Pharmaceuticals’ Zepzelca combination meets endpoints in lung cancer trial
Jazz Pharmaceuticals announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca in combination with the PD-L1 inhibitor atezolizumab – Tecentriq- compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC, following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab demonstrated a statistically significant improvement in the pr
BenzingaJazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s (OTC:RHHBY) atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab showed a statistically
